NLS Pharma News

AI in Pharma & MedTech: Compliance, regulations & GxP boundaries | Live webinar

AI is transforming Pharma and MedTech, but compliance defines the boundaries.

Financing – March 3, 2026

SynAct Pharma has carried out a directed issue of new shares

Through the directed issue, the company will receive approximately SEK 51.9 million.

Financing – February 24, 2026

Oncopeptides carries out a rights issue of approx SEK 200 million

The Board of Directors has resolved to carry out a new share issue of approximately SEK 200 million with preferential rights for the company’s existing shareholders based on the authorization granted by the Annual General Meeting on 22 May 2025.

Precision monitoring in life science cleanrooms with Vaisala Origo

Vaisala’s new Origo modular measurement platform provides accurate, stable monitoring of key parameters in pharmaceutical, biotech, and other critical cleanrooms, combining flexible probe configurations, quick commissioning, long-term reliability to protect product quality, reduce risk, and improve control in critical spaces.

Legal Advice article – February 10, 2026

Novo Nordisk sues Hims & Hers over alleged unsafe Wegovy and Ozempic knock‑offs

On 9 February 2026, Novo Nordisk announced it has filed a lawsuit against U.S. telehealth company Hims & Hers, alleging that the firm is offering compounded, non‑FDA‑approved versions of Wegovy and Ozempic that could put patients at risk.

Clinical Trials

Clinical Trials – February 10, 2026

Lundbeck presents real-world data highlighting improvements in migraine

The company has announced six-month data from the 12-month, real-world INFUSE study, evaluating the effectiveness of Vyepti in adults with migraine who had failed at least one preventive anti-calcitonin gene–related peptide (aCGRP) treatment, at any time point previously.

Clinical Trials – February 2, 2026

SynAct Pharma initiates Phase 2 study in respiratory insufficiency

SynAct Pharma has initiated a Phase 2 study (RESPIRE) with resomelagon in patients hospitalized with respiratory insufficiency due to viral infections.

Clinical Trials – January 27, 2026

Takeda’s zasocitinib meets primary and secondary endpoints in Phase 3 study

The results showed that approximately 30 percent of patients achieved complete skin clearance (PASI 100) at week 16, and that more than half reached almost complete clearance (PASI 90).

Clinical Trials – January 27, 2026

DexTech Medical’s myeloma study, completed at the end of February

The results show that all patients responded positively to the ODX treatment, with a transition from progressive disease to stable disease.

Clinical Trials – January 12, 2026

Elicera Therapeutics announces final data from its Phase I/IIa trial

Elicera Therapeutics has announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases.

Clinical Trials – January 9, 2026

Sobi to advance Gamifant in interferon-gamma-driven sepsis

Sobi has announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.

Clinical Trials – January 8, 2026

Herantis Pharma reports encouraging data from Phase 1b trial

Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson’s disease, states the company.

Clinical Trials – January 7, 2026

BioInvent reports promising Phase 2a study data

BioInvent International has announced encouraging interim results from its ongoing Phase 2a signal-seeking study evaluating BI-1808, a novel immuno-oncology candidate, in combination with MSD’s anti-PD-1 therapy KEYTRUDA in patients with recurrent ovarian cancer who have progressed following platinum-based therapy.

Clinical Trials – January 2, 2026

Hemab Therapeutics announces positive complete Phase 2 data

Hemab Therapeutics has announced positive results from its completed Phase 2 multiple ascending dose (MAD) portion of the CL-101 study of sutacimig for the prophylactic treatment of Glanzmann thrombasthenia (GT).

Clinical Trials – December 17, 2025

Zelluna publishes new preclinical data

Zelluna has announced the publication of preclinical data for its lead candidate, ZI-MA4-1, in the peer-reviewed journal Immunotherapy Advances.

Profiles in Pharma

Profiles in Pharma – April 2, 2025

The Jalkanens: A shared thirst for knowledge

For Sirpa and Markku Jalkanen of Finland, M.D. and Ph.D., married, immunotherapy researchers, working together came as naturally as a courtship.

Profiles in Pharma – November 1, 2023

Jonina Gudmundsdottir, Coripharma

In the heart of Iceland’s life sciences industry, Jonina Gudmundsdottir, the CEO of Coripharma, is making her mark. With a deep understanding of the industry’s challenges and a relentless drive for excellence, Gudmundsdottir has steered Coripharma toward transformative success. Iceland’s life sciences industry has thrived in recent years, propelled by its unique strengths. With a […]

Profiles in Pharma – July 3, 2023

Deborah Dunsire

The CEO of Lundbeck, who announced that she will retire last week, did not initially intend to join the life science industry, but it captivated her more than 30 years ago, and the ability to transform lives still drives her to this day. For more than 100 years, Lundbeck has been at the forefront of […]

Profiles in Pharma – October 1, 2021

Malin Parkler – Passionate about science, health & leadership

Malin Parkler, CEO of Pfizer Sweden, is driven by curiosity and a passion to build knowledge and evolve the life science industry – with the ultimate goal to yield real benefits for patients. Rarely has the world been more in need of leaders. As the global community struggled with the COVID-19 pandemic last year, people […]

Profiles in Pharma – August 15, 2019

Katarina Ageborg, CEO AstraZeneca Sweden

Few companies are as synonymous with Sweden as AstraZeneca and few CEOs as visible. Yet, Katarina Ageborg, AstraZeneca Sweden’s new CEO, prefers not to think about being center stage, but instead about what her position can do for the company, Sweden and the pharmaceutical industry as a whole. “I don’t think about it that way […]

Profiles in Pharma – July 1, 2017

Embracing diversity – for the sake of true innovation

Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief in the need for diversity to truly bring forth innovation. A view that is also deeply incorporated in her job as Head of MedImmune. Editor’s note: In 2019 Bahika Jallal left MedImmune and became the […]

Profiles in Pharma – March 22, 2017

“The scientist in me wants to make a difference”

After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further to start something on her own. As founder and CEO of PILA PHARMA she hopes to bring a new oral anti-diabetic agent to the market. What made you take the leap to go on your […]

Profiles in Pharma – March 8, 2017

“We have to embrace the new era of diabetes care”

Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development strategy, the new era of diabetes care and his 25 year-long passion for his job. The changing diabetes market, with increasing competition and high prices for diabetes products in the US, has made the world’s […]

Profiles in Pharma – February 16, 2017

From regulator to pharma industry specialist

Dr. Thomas Lönngren, former head of the EMA and today a pharmaceutical consultant, provides some insights on the aftermath of Brexit, describes current challenges the industry is facing and takes a short walk down memory lane on his career journey. The summer of 2016 will be remembered for many things; record temperatures, terrorist acts in […]

Profiles in Pharma – April 21, 2014

Jan Lundberg: The long view of R&D at Eli Lilly

Like sports, R&D requires team spirit, commitment, and a long view says Dr. Jan Lundberg, Lilly executive vice president for science and technology, and president of Lilly Research Laboratories. Dr. Jan Lundberg’s online bios and YouTube videos portray a steely pharmaceutical executive whose idea of fun is a 90 km ski race. It’s all true. […]